Influence of a pentoxifylline-analogue on the granulocyte-mediated pulmonary mediator release and vascular reaction.
The influence of a novel pentoxifylline-analogue, HWA 138, on the polymorphonuclear neutrophil leukocyte (PMN)-mediated changes in pulmonary resistance and mediator release was investigated in the isolated perfused and ventilated rabbit lung model. Isolated, washed human granulocytes were injected into the pulmonary artery and stimulated by either 10(-6) mol/L N-formyl-L-leucin-methionyl-L-phenylalanine (FMP) or 3 x 10(-8) mol/L phorbol 12-myristate 13-acetate (PMA) in the presence or absence (controls) of HWA 138 (10(-4) mol/L). Shortly after granulocyte activation, there was a massive generation and release of thromboxane (> 110 pg/ml) and histamine (150-400 nmol/L), with an acute increase of pulmonary artery pressure (> 8 mmHg) in the control groups. Application of HWA 138 almost completely suppressed mediator formation and release as well as pulmonary vascular reaction in the FMP stimulated group. In contrast to this, HWA 138 was unable to influence either mediator release, the pulmonary pressure reaction or interstitial edema formation following PMA stimulation. In the present model, HWA 138 is supposed to be effective via granulocytes by decreasing mediator release, obviously due to burst reaction.
Koch
T
T
Department of Anaesthesiology and Operative Intensive Care, Faculty for Clinical Medicine Mannheim, University of Heidelberg, Germany.
Neuhof
H
H
Duncker
H P
HP
Stein
A
A
Möschet
B
B
Schönharting
M
M
van Ackern
K
K
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006636:Histamine Release / Q000187:drug effects*; D008168:Lung / Q000098:blood supply* / Q000187:drug effects / Q000502:physiology; D008297:Male; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D010431:Pentoxifylline / Q000031:analogs & derivatives* / Q000494:pharmacology; D011651:Pulmonary Artery / Q000502:physiology; D011817:Rabbits; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013929:Thromboxane B2 / Q000378:metabolism*; D014655:Vascular Resistance / Q000187:drug effects
C062028:1-(5-hydroxy-5-methylhexyl)-3-methylxanthine; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D009240:N-Formylmethionine Leucyl-Phenylalanine; D013755:Tetradecanoylphorbol Acetate; D010431:Pentoxifylline